Live Support

Two UK directors of Vertex Pharmaceuticals, the company in a standoff with the NHS over the high price of its breakthrough cystic fibrosis drug, made more than £15m from share options in 2017, the Guardian can reveal.

Vertex refuses to drop the price of Orkambi, a drug that treats the underlying causes of the life-shortening disease, to a level the NHS says it can afford. The two-year negotiations have been in stalemate for six months, while children and young adults with cystic fibrosis who could be helped suffer infectins and irretrievably lose some of their lung function.


The Guardian

You need to be a member of People's Forum to add comments!

Join People's Forum

Email me when people reply –

Discussion Area

This area is for people to post and view discussions. You can use the the tabs at the top of the page to filter the discussion to the topics you want.

If you would like to start a discussion please click Add Discussion